Information Provided By:
Fly News Breaks for August 7, 2019
Aug 7, 2019 | 13:08 EDT
After the FDA issued an update on its analysis of a late mortality signal in patients treated for peripheral artery disease in the femoropopliteal artery with paclitaxel-coated balloons and paclitaxel-eluting stents, Piper Jaffray analyst Matt O'Brien said the FDA's conclusion "likely keeps the status quo as far as usage in 2019." However, he still sees a significant patency benefit with these devices and expects further clinical data to resolve doctor's concerns in the longer-term, O'Brien stated. Makers of paclitaxel-coated devices include Boston Scientific (BSX) and Medtronic (MDT).